Hay fever
Information
- Disease name
- Hay fever
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05960266 | Active, not recruiting | Early Phase 1 | Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study | October 23, 2023 | December 31, 2024 |
| NCT00163488 | Completed | Phase 3 | Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) | January 2005 | August 2005 |
| NCT00163501 | Completed | Phase 3 | Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404) | December 2003 | April 2005 |
| NCT00163514 | Completed | Phase 3 | Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403) | May 2004 | July 2005 |
| NCT00189917 | Completed | Phase 1 | Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders | April 2004 | |
| NCT00261287 | Completed | Phase 3 | Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) | November 2005 | June 2006 |
| NCT00305487 | Completed | Phase 3 | Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) | March 2006 | October 2006 |
| NCT00384475 | Completed | Phase 3 | A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) | October 2006 | January 2007 |
| NCT00574210 | Completed | Phase 2 | PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) | October 2007 | February 2008 |
| NCT00574379 | Completed | Phase 2 | Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR | December 2007 | March 2008 |
| NCT00658918 | Completed | Phase 3 | To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405) | September 2004 | November 2005 |
| NCT00659503 | Completed | Phase 3 | Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407) | February 2005 | November 2005 |
| NCT00659594 | Completed | Phase 3 | Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) | November 2004 | September 2005 |
| NCT00659841 | Completed | Phase 3 | To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401) | December 2003 | February 2005 |
| NCT01024608 | Completed | Phase 3 | Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) | December 31, 2009 | February 28, 2010 |
| NCT01137357 | Completed | N/A | Probiotics for Reduction Of Markers In Subjects With Allergy | November 2008 | December 2008 |
| NCT01308021 | Completed | Phase 2 | Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis | December 2010 | December 2011 |
| NCT01506375 | Completed | Phase 2 | Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant | November 2011 | April 2013 |
| NCT01660737 | Completed | Observational Study With PASCALLERG ® in Patients With Hay Fever | February 2012 | July 2013 | |
| NCT02156791 | Completed | Phase 2 | Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM | August 2013 | December 2013 |
| NCT02560948 | Completed | Phase 3 | Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis | December 2015 | August 2016 |
| NCT02619331 | Completed | N/A | Evaluation of High Speed Laser Doppler Imaging Technology | February 2008 | September 2011 |
| NCT02932774 | Completed | Phase 4 | Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) | March 2001 | July 2001 |
| NCT06457269 | Completed | N/A | Evaluating the Potential of Large Language Models for Respiratory Disease Consultations | October 1, 2023 | April 4, 2024 |
| NCT04622917 | Completed | Phase 4 | Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. | April 10, 2019 | May 31, 2023 |
| NCT00078195 | Completed | Phase 2 | Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies | April 2003 | May 2005 |
| NCT04326309 | Completed | Audio Data Collection for Identification and Classification of Coughing | March 25, 2020 | January 24, 2022 | |
| NCT03724240 | Unknown status | Phase 3 | Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis | January 2, 2019 | December 2019 |
| NCT00247520 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy Study of rEV131 in Allergic Rhinitis | May 2005 | August 2005 |